Bedrijfsoverzicht
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical entity that focuses on the development of a pipeline comprising novel product candidates directed at validated molecular targets within indications characterized by significant unmet medical needs in the United States. The company operates within the Healthcare sector and specifically functions in the Biotechnology industry, a classification that signifies its engagement in the creation of biological medicines rather than generic pharmaceuticals or medical devices. As of the latest reported data, the entity maintains a market capitalization of $14.86M and employs a workforce of 28 individuals, while generating total annual revenue of $1.00M over the trailing twelve-month period. These financial metrics indicate that Applied Therapeutics, Inc. occupies a niche position in the market with a relatively small market cap relative to its revenue, suggesting a capital-intensive growth stage typical for early-phase biotechnology firms where substantial resources are allocated toward research and development rather than immediate profit generation.
Financiële gezondheid
Over the trailing twelve months, the company reported a revenue of $1.00M, a net income of $-18,138,000, and an EBITDA of $-99,611,000. The substantial disparity between the reported revenue of $1.00M and the negative net income of $-18,138,000 reveals a highly aggressive cost structure where operating expenses, likely dominated by research and development costs, significantly outweigh sales income. The free cash flow stands at $-128,157,504, which indicates that the company is currently burning through cash reserves to fund its operations and pipeline advancement, thereby limiting its immediate financial flexibility without further capital raises. Analysis of the three primary margins shows a gross margin of 0.0%, an operating margin of -1796.7%, and a profit margin of 0.0%; the zero gross margin suggests that cost of goods sold may be equal to or exceeding revenue, while the deeply negative operating margin highlights the heavy expense burden typical of clinical-stage development. In terms of leverage, the company holds $11.95M in cash against $2.50M in debt, a position that appears conservative on the surface, though the debt-to-equity ratio is listed as N/A due to the equity dynamics of a loss-making entity. The current ratio is 0.96, which implies that the company's current assets are slightly insufficient to cover its current liabilities, signaling potential short-term liquidity constraints that require careful management. Return on Equity is reported at -680.5% and Return on Assets at -88.3%, metrics that reveal the company is currently unable to generate positive returns on the capital invested by shareholders or creditors, reflecting the high-risk nature of its developmental phase.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A, while the forward P/E is listed as -0.26; the absence of a trailing P/E implies that the company has not generated positive earnings over the past year, and the negative forward P/E suggests that analysts or the market are pricing in future losses or are using a non-standard metric due to the lack of positive earnings expectations. The price-to-book ratio is -25.75, a figure that indicates the market is valuing the company at a significant discount to its book value, often a characteristic of distressed or speculative biotechnology stocks where assets may not yet be fully monetized. The price-to-sales ratio stands at 14.86 and the EV/EBITDA is -0.05; these alternative valuation metrics suggest that the company is being valued primarily on its future potential rather than current profitability, with the negative EV/EBITDA reinforcing the presence of significant accumulated losses. The 52-week high is $1.50 and the 52-week low is $0.09; without a specific current price provided in the source data, the valuation range is defined by this volatility, indicating the stock has experienced a massive expansion from its low to its high within a single year. The beta value is 2.08, which explains that the stock price is expected to exhibit high volatility relative to the broader market, potentially moving more than twice as much as the market index during periods of instability.
Growth & Income
The company has achieved a revenue growth rate of 719.7% year-over-year, while the earnings growth rate is N/A due to the absence of positive earnings; this divergence implies that revenue expansion is occurring independently of profitability, which is standard for biotechnology firms scaling up clinical trials but not yet reaching commercial milestones. Regarding income distribution, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. Since the earnings growth rate is N/A and net income is negative, the payout ratio is not sustainable in the traditional sense, as the firm retains all available resources to fund its development pipeline rather than paying out distributions. Consequently, Applied Therapeutics, Inc. operates with a growth-oriented profile where the reinvestment of earnings into research and development is the primary strategy, rather than providing current income to investors.